The UK’s fastest growing private companies: Hot 100 2015 – (22) Flynn Pharma
2 min read
26 June 2015
Pharmaceuticals business Flynn Pharma concentrates on developing smaller or lesser-known prescription products that larger firms don't prioritise.
Name: Flynn Pharma
Industry/sector: Retail and related services
Date founded: 1994
The boss: David Walters
Location: South East
Latest turnover: £54m
Three-year compound growth rate (%): 56.05
Latest EBITDA: £13.2m
Flynn Pharma is a specialist pharmaceutical firm based in Stevenage, Hertfordshire. Its particular focus is on buying and commercialising products that from secondary healthcare sectors that aren’t considered of importance at larger firms..
The company said its “goal is to be the foremost European provider of specialty products in these targeted and underserved therapeutic categories”.
Having originally launched back in 1994, the company started off by distributing sedative products and in 2005 it acquired a series of oral and injectable antibiotics to broaden its operation.
Further along in 2007 and Flynn Pharma launched a range for ADHD treatment, going on to buy private German pharmaceutical company GmbH for access to hospital goods.
In 2012 Flynn was appointed as Neurim’s marketing partner for Circadin, sustained release melatonin, in the UK and Ireland and has successfully re-launched this product
In addition Flynn Pharma became the UK partner of Innocoll for the marketing and distribution of the CollaGUARD adhesion barrier. Another addition to the Flynn range in 2012 was Epanutin from Pfizer.
“In order that this vitally important product could continue to be made available to patients Flynn has changed the name to Phenytoin Sodium Flynn Hard Capsules and is putting in place measures to ensure the integrity of the supply chain,” the company said.
Given the company’s origins and business history, it has sales and marketing channels across the UK, Ireland and Germany.
With a CAGR of 56.05 per cent, the firm claims its long-term growth comes organically from its current portfolio of products and through new item launches in domestic markets, along with active expansion into new locations and continued takeovers.
Interestingly, Flynn also considers itself to be an innovator and embraced emerging technology platform, augmented reality (AR). The service was developed to provide patients with digital instructions when customers scan their mobile over instruction leaflets.